AbbVie (NYSE:ABBV) Releases FY 2026 Earnings Guidance

AbbVie (NYSE:ABBV) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 14.370-14.570 for the period, compared to the consensus EPS estimate of 14.260. The company issued revenue guidance of -, compared to the consensus revenue estimate of $67.1 billion. AbbVie also updated its Q1 2026 guidance to 2.970-3.010 EPS.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ABBV. Raymond James Financial set a $256.00 price target on AbbVie in a research note on Monday, November 3rd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $258.00 price target on shares of AbbVie in a research note on Thursday, January 15th. Cantor Fitzgerald set a $250.00 price target on AbbVie and gave the company an “overweight” rating in a report on Thursday, October 9th. DZ Bank cut AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target for the company. in a report on Tuesday, November 4th. Finally, Berenberg Bank set a $275.00 target price on AbbVie in a research report on Tuesday, January 20th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus price target of $251.00.

AbbVie Trading Up 2.2%

Shares of NYSE ABBV traded up $4.89 during midday trading on Friday, reaching $223.91. 2,988,129 shares of the stock were exchanged, compared to its average volume of 7,542,148. AbbVie has a 52-week low of $164.39 and a 52-week high of $244.81. The stock has a 50 day moving average price of $223.81 and a 200-day moving average price of $219.14. The company has a market capitalization of $395.74 billion, a P/E ratio of 94.87, a P/E/G ratio of 0.89 and a beta of 0.35.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The business had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same period in the previous year, the company posted $2.16 earnings per share. The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts forecast that AbbVie will post 12.31 earnings per share for the current year.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Analyst bullishness — Morgan Stanley raised its price target to $270 with an Overweight rating, supporting upside expectations and likely contributing to buying interest. AbbVie (NYSE:ABBV) Price Target Raised to $270.00 at Morgan Stanley
• Positive Sentiment: Quarterly beat and FY strength — AbbVie reported Q4 revenue and EPS beats driven by Skyrizi and Rinvoq, and its 2026 EPS guidance was viewed as strong by some outlets, underpinning confidence in immunology-led growth. AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs
• Positive Sentiment: Clinical/real-world data tailwind — Positive real‑world Rinvoq data from Japan (ankylosing spondylylitis) reinforces commercialization momentum and supports longer-term revenue prospects for Rinvoq. AbbVie’s Real-World RINVOQ Data in Japan: What It Means for Ankylosing Spondylitis Investors
• Neutral Sentiment: Investor commentary: management is pitching “new growth engines” (Skyrizi/Rinvoq/neurology) as the lead for future growth; this frames Q4 strength but leaves open how broad-based the recovery will be. AbbVie Earnings Call: New Growth Engines Take Lead
• Neutral Sentiment: Market reaction coverage: roundups note both the beat and mixed segment performance — useful context but not a clear directional catalyst on its own. Earnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myers’ waiting game
• Negative Sentiment: Shares initially gapped down after the print — although results beat in aggregate, investors punished areas that missed or showed softness, driving intraday selling pressure. AbbVie (NYSE:ABBV) Shares Gap Down Following Weak Earnings
• Negative Sentiment: Near-term guidance misses: AbbVie’s Q1 revenue/EPS range landed below Street expectations (Q1 EPS guide weaker than consensus), which spurred concern that near-term topline could be softer despite FY strength. AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat ’26 View
• Negative Sentiment: Diversification and aesthetics concerns — analysts/notes highlight that strong immunology growth masks weakness in oncology and aesthetics, and some voices warn ABBV may remain dependent on M&A or milestones to fill gaps. AbbVie’s Immunology Fortress Can’t Hide Cracks In Diversification (Downgrade)

Institutional Trading of AbbVie

Several institutional investors and hedge funds have recently added to or reduced their stakes in ABBV. Greenline Partners LLC purchased a new stake in AbbVie during the 3rd quarter valued at $453,000. Keystone Financial Group lifted its position in shares of AbbVie by 7.6% during the 3rd quarter. Keystone Financial Group now owns 19,672 shares of the company’s stock valued at $4,562,000 after buying an additional 1,393 shares in the last quarter. Morningstar Investment Management LLC lifted its holdings in AbbVie by 1,650.5% in the 3rd quarter. Morningstar Investment Management LLC now owns 34,293 shares of the company’s stock worth $7,940,000 after purchasing an additional 32,334 shares in the last quarter. Kestra Private Wealth Services LLC increased its stake in AbbVie by 4.5% in the 3rd quarter. Kestra Private Wealth Services LLC now owns 171,091 shares of the company’s stock worth $39,614,000 after acquiring an additional 7,387 shares during the last quarter. Finally, NewEdge Advisors LLC increased its position in shares of AbbVie by 4.6% during the 3rd quarter. NewEdge Advisors LLC now owns 581,192 shares of the company’s stock valued at $134,569,000 after purchasing an additional 25,619 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.